Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alterity Therapeutics Limited

Market Cap 71.19M 61.78M 56.94M 53.36M 99.69M 6.82B 102M 679M 263M 3.29B 267M 261M 11.42B P/E Ratio 2026 *
-0.19x
P/E Ratio 2027 * -0.19x
Enterprise Value 26M 22.56M 20.8M 19.49M 36.41M 2.49B 37.17M 248M 96.05M 1.2B 97.6M 95.49M 4.17B EV / Sales 2026 *
7.59x
EV / Sales 2027 * 18.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alterity Therapeutics Limited

1 day+11.24%
1 week+10.00%
Current month+10.00%
1 month-1.00%
3 months+23.75%
6 months+10.00%
Current year+23.75%
1 week 0.45
Extreme 0.45
0.52
1 month 0.4
Extreme 0.4
0.52
Current year 0.35
Extreme 0.35
0.55
1 year 0.35
Extreme 0.35
0.85
3 years 0.1
Extreme 0.1
0.95
5 years 0.1
Extreme 0.1
2.1
10 years 0.1
Extreme 0.1
20.5
Manager TitleAgeSince
Chief Executive Officer 65 2021-01-06
Director of Finance/CFO - 2024-09-29
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 2005-07-28
Director/Board Member 47 2011-08-07
Director/Board Member 65 2025-11-20
Date Insider Type Main position Quantity % Market Cap.
04-14Other

Chief Executive Officer

346,123,874 3.1826%
04-09Other

Director

56,060,607 0.5155%
04-09Other

Director

32,424,243 0.2981%

Financials

2026 *2027 *
Net sales 3.42M 2.97M 2.74M 2.57M 4.8M 328M 4.9M 32.68M 12.65M 158M 12.86M 12.58M 550M 1.6M 1.39M 1.28M 1.2M 2.24M 153M 2.29M 15.27M 5.91M 73.86M 6.01M 5.88M 257M
Net income -13.44M -11.66M -10.75M -10.08M -18.82M -1.29B -19.22M -128M -49.66M -620M -50.46M -49.37M -2.16B -22.29M -19.34M -17.83M -16.71M -31.22M -2.13B -31.87M -213M -82.35M -1.03B -83.68M -81.87M -3.58B
Net Debt -45.19M -39.21M -36.15M -33.87M -63.28M -4.33B -64.6M -431M -167M -2.09B -170M -166M -7.25B -40.88M -35.48M -32.7M -30.64M -57.25M -3.91B -58.44M -390M -151M -1.89B -153M -150M -6.56B
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
9
Sector
-
Date Price Change Volume
26-06-12 0.4950 $ +11.24% 217,606
26-06-09 0.4650 $ +3.33% 0
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.4650AUD
Average target price
2.280AUD
Spread / Average Target
+390.32%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!